Level B· Emerging clinical evidence with positive signalsClinical TrialPubMed

Influence of patient related factors on number of mesenchymal stromal cells reached after in vitro culture expansion for clinical treatment.

Qayyum AA., Kaur KP., Mathiasen AB., Haack-Sørensen M., Ekblond A., Kastrup J.

Clinical Trial with a reported sample of 111 on Cardiovascular Disease, Stroke Research, published in Scand J Clin Lab Invest (2017) — summary generated from the PubMed abstract.

Open my reading list
Level B· Emerging clinical evidence with positive signalsEvidence level of this study

Several human studies show positive signals, while research methods and sample sizes continue to develop.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Clinical Trial
Journal
Scand J Clin Lab Invest (2017)
Country
England
Reported sample size
111
Source database
PubMed
PMID
28737959
DOI
10.1080/00365513.2017.1354258
Citations
5

Abstract (original English)

Number of stromal cells injected in patients with ischaemic heart disease (IHD) may be of importance for the treatment efficacy, which in turn may be influenced by various patient-related factors. In this study, we investigate whether patient-related factors influence the number of autologous stromal cells reached after in vitro culture expansion for clinical therapy. Culture expansion data from 111 patients with IHD treated with autologous stromal cells in three clinical trials were used. We correlated the final cell count after two passages of cultivation with different patient factors. There was a significant relation between body mass index (BMI) and the number of adipose derived stromal cells (ASCs) reached after culture expansion and for all patients included into the three studies (r = 0.375, p = .019 and r = 0.200, p = .036, respectively). Moreover, there was a significantly higher number of ASCs reached in patients with hypertension compared to those without hypertension and for all patients overall (68.8 ± 39.6 × 10 6 vs. 39.1 ± 23.6 × 10 6 , p = .020 and 62.0 ± 55.0 × 10 6 vs. 29.0 ± 19.3 × 10 6 , p < .001, respectively). The same tendency was seen with bone marrow derived mesenchymal stromal cells (MSCs) in patients with hypertension compared to those without hypertension (58.4 ± 61.8 × 10 6 vs. 22.6 ± 13.3 × 10 6 , p < .001) and in males compared to females (56.4 ±

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.

Evidence level

Several human studies show positive signals, while research methods and sample sizes continue to develop.

How we grade evidence
AgedBody Mass IndexCell CountCell Culture TechniquesCell ProliferationCholesterolFemaleHumansMaleMesenchymal Stem Cell Transplantation

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research